Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease
Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease
复制标题
DOI：
10.1007/s10067-010-1498-z
复制
发表时间：
2010-10-01
影响因子：
3.4
通讯作者：
Sakkas, Lazaros I.
中科院分区：
文献类型：
--
作者：
Koutroumpas, Athanasios;Ziogas, Athanasios;Sakkas, Lazaros I.
本研究旨在评估淋巴细胞增殖抑制剂霉酚酸酯（MMF）对系统性硬化症（SSc）相关间质性肺病（SSc- ild）患者肺功能和皮肤的影响。在这项回顾性研究中，我们回顾了10例SSc- ild患者的医疗档案（8例女性，10例弥漫性SSc，平均年龄59.7 +/- 12.7岁，病程7.7 +/- 4.7年）。患者接受MMF治疗（2 g/天）12个月。在基线和12个月时评估肺功能测试和改良罗德曼总皮肤评分（mRTSS）。结果采用配对学生t检验进行分析。MMF组患者在12个月时强迫肺活量显著增加，一氧化碳弥散量无显著增加（p分别为0.04和0.66）。对mRTSS没有影响。MMF在治疗12个月后稳定SSc-ILD的肺功能。
This study aimed to assess the effect of mofetil mycophenolate (MMF), an inhibitor of lymphocyte proliferation, on lung function and skin in patients with systemic sclerosis (SSc)-associated interstitial lung disease (SSc-ILD). In this retrospective study, we reviewed the medical files of 10 patients with SSc-ILD (eight females, 10 patients with diffuse SSc; mean age, 59.7 +/- 12.7 years; disease duration, 7.7 +/- 4.7 years). Patients were treated with MMF (2 g/day) for 12 months. Lung function tests and the modified Rodnan total skin score (mRTSS) were assessed at baseline and at 12 months. Results were analyzed by paired Student's t test. There was a significant increase in forced vital capacity and a nonsignificant increase in carbon monoxide diffusing capacity at 12 months in patients on MMF (p = 0.04 and 0.66, respectively). There was no effect on mRTSS. MMF stabilizes lung function of SSc-ILD after 12 months of treatment.